LM
LMLLF.US Pharmadrug Inc
- Market cap
- USD 805K
- P/E
- -
- P/B
- 0.66x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LMLLF.US undervalued?
Graham numberThe Graham number of Pharmadrug Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmadrug Inc fundamental analysis
No fundamental analysis for Pharmadrug Inc yet.
Pharmadrug Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmadrug Inc
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a …
Full company profilePharmadrug Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmadrug Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 611K | 684K | 7.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -110.00 | 0.00 | - | 253K | 182K | -2.16K | -2.26K | -26.2K | - | -50.2K | - |
| Operating Income | -1.09M | -114K | -951K | -5.09M | -3.84M | -2.70M | -2.34M | -1.34M | -583K | -226K | -113K |
| EBITDA | -1.09M | -114K | -951K | -5.73M | -4.25M | -4.21M | -2.34M | -1.34M | -583K | -176K | -87.7K |
| Net Income | -7.51M | -115K | -3.89M | -6.29M | -5.15M | -5.87M | -8.88M | -13.2M | -793K | -383K | -862K |
| EPS | -13 | -0.21 | -1.98 | -0.63 | -0.25 | -0.12 | -0.18 | -0.23 | -0.01 | 0.00 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 115K | 100K | 1.06M | 10.4M | 13.7M | 19.5M | 12.1M | 1.20M | 712K | 551K | 752K |
| Total Liabilities | 72.0K | 21.1K | 1.55M | 5.92M | 3.12M | 2.66M | 3.28M | 2.66M | 1.96M | 2.20M | 2.46M |
| Shareholders' Equity | 42.5K | 79.0K | -490K | 2.98M | 9.33M | 16.9M | 8.84M | -1.70M | -1.40M | -1.76M | -1.80M |
| Cash & Short-term Investments | 12.6K | 1.07K | 155K | 73.7K | 4.40M | 1.30M | 329K | 423K | 75.0K | 23.2K | 23.1K |
| Total Debt | 130K | 1.03M | 960K | 3.12M | 1.13M | 866K | 1.42M | 1.77M | 1.35M | 1.52M | 1.81M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -43.4K | -130K | -1.29M | -2.34M | -1.41M | -4.13M | -2.26M | -672K | -757K | -87.5K | -180K |
| Capital Expenditure | 186K | 9.79K | 9.79K | 19.0K | 18.0K | 42.7K | 0.00 | 0.00 | 12.0K | 0.00 | 0.00 |
| Free Cash Flow | -229K | -130K | -1.29M | -2.36M | -1.43M | -4.17M | -2.26M | -672K | -769K | -87.5K | -180K |
| Ratios | |||||||||||
| ROE | -17,657.7% | -145.4% | - | -211.2% | -55.2% | -34.8% | -100.5% | - | - | - | - |
| ROA | -6,558.9% | -114.7% | -365.8% | -60.6% | -37.6% | -30.1% | -73.3% | -1,100.8% | -111.4% | -69.5% | -114.6% |
| Net Profit Margin | - | - | - | -1,030.2% | -753.3% | -83,806.5% | - | - | - | - | - |
| Debt to Equity | 3.05x | 13.08x | - | 1.05x | 0.12x | 0.05x | 0.16x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmadrug Inc dividends
Pharmadrug Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Oct 24, 2023.
Who owns Pharmadrug Inc
- Insiders 0.88%
- Institutions 0.00%
- Public & others 99.12%
- Shares outstanding 134M
- Free float 107M
Pharmadrug Inc company profile
- Company name
- Pharmadrug Inc
- Ticker
- LMLLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 77 King Street West, Toronto, ON, Canada, M5K 1H1
- Phone
- 416 400 7086
- Website
- pharmadrug.ca
About Pharmadrug Inc
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions. It has a license agreement with Southwest Research Institute. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug Inc. was incorporated in 2011 and is based in Toronto, Canada.
Pharmadrug Inc management
2- Dr. David M. Kideckel M.B.A., Ph.D.Executive Chairman of the Board · born 1981
- Mr. Kyle Michael Appleby CA, CPAChief Financial Officer · born 1975